Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2007

Pfizer and pSivida Ink $165M Deal

  • Pfizer gained access to pSivida's controlled drug delivery technologies, including the Medidur™ technology in ophthalmic applications.

    Under this exclusive, worldwide CRADA, pSivida stands to earn $155 million in development and sales related milestones. Pfizer will fund the total cost of the joint research program aimed at developing products using pSivida’s technologies.

    Pfizer also reports that it invested $5 million in pSivida and plans to contribute an additional $5 million subject to certain conditions.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »